BRIEF published on 07/28/2025 at 07:35, 1 year ago MaaT Pharma Secures €37.5 Million Loan to Boost Hemato-Oncology Programs Clinical Development EIB Loan Hemato-oncology Microbiome Therapy Xervyteg® Approval
PRESS RELEASE published on 07/28/2025 at 07:30, 1 year ago Inside Information / Other news releases MaaT Pharma secures €37.5 million loan from the European Investment Bank to advance clinical programs in Hemato-Oncology. Funding supports late-stage assets Xervyteg® and MaaT033 European Investment Bank Clinical Programs Loan MaaT Pharma Hemato-oncology
BRIEF published on 06/24/2025 at 20:05, 1 year 1 month ago MaaT Pharma General Meeting: Results and Appointments Kepler Cheuvreux Resolutions General Assembly MaaT Pharma Appointment Of President
PRESS RELEASE published on 06/24/2025 at 20:00, 1 year 1 month ago Inside Information / Other news releases MaaT Pharma presents Annual General Meeting results, with shareholders approving most resolutions. Jean-Marie Lefevre appointed Chairman. Liquidity contract with Kepler Cheuvreux maintained Annual General Meeting Shareholders Liquidity Contract MaaT Pharma Jean-Marie Lefevre
BRIEF published on 06/19/2025 at 19:05, 1 year 1 month ago MaaT Pharma Advances Xervyteg® Commercialization Efforts European Market Clinical Trials Oncology Microbiome Xervyteg®
PRESS RELEASE published on 06/19/2025 at 19:00, 1 year 1 month ago Inside Information / Other news releases MaaT Pharma provides business update & highlights key milestones for 2025, including MA application submission for Xervyteg, strategic focus in Europe & US trial launch Business Update Clinical-stage Biotechnology MaaT Pharma Key Milestones Xervyteg
BRIEF published on 06/13/2025 at 07:35, 1 year 2 months ago MaaT Pharma Reveals Promising Data for Xervyteg® at EHA Congress Clinical Efficacy Safety Profile Xervyteg® AGvHD EMA Application
PRESS RELEASE published on 06/13/2025 at 07:30, 1 year 2 months ago Inside Information / Other news releases MaaT Pharma presents updated positive data for Xervyteg® in treating acute Graft-versus-Host Disease at EHA Congress, validating high efficacy observed in pivotal ARES study MaaT Pharma Acute Graft-versus-Host Disease EMA Approval Xervyteg EAP Data
BRIEF published on 05/12/2025 at 07:35, 1 year 3 months ago Promising data for MaaT033 in ALS Microbiome Amyotrophic Lateral Sclerosis MaaT033 Safety And Tolerability Phase 1b Clinical Trial
BRIEF published on 04/08/2025 at 07:35, 1 year 4 months ago MaaT Pharma Announces Positive Interim Safety Results for MaaT033 Phase 2B Trial MaaT Pharma MaaT033 Allo-HSCT DSM Safety
Published on 08/15/2026 at 00:15, 2 days 4 hours ago Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 2 days 4 hours ago AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:00, 2 days 5 hours ago Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
Published on 08/17/2026 at 02:00, 2 hours 21 minutes ago Sandoz announces strategic collaboration with Henlius on up to 10 biosimilars, further expanding industry-leading pipeline
Published on 08/16/2026 at 19:40, 8 hours 41 minutes ago APIC delivers 55% EBITDA growth in the first half of 2026, reaching USD 44 million
Published on 08/16/2026 at 13:40, 14 hours 41 minutes ago Ajax says goodbye to Godts with a classy message in Paris: THE FUTURE BELONGS TO YOUNG GODTS
Published on 08/16/2026 at 09:45, 18 hours 36 minutes ago Ragnarok Zero: Global Set to Officially Launch on August 18
Published on 08/16/2026 at 06:15, 22 hours 6 minutes ago Garvee Spotlights Home & Garden Essentials for the Late-Summer to Early-Autumn Transition
Published on 08/10/2026 at 18:00, 6 days 10 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 6 days 16 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 6 days 16 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 6 days 18 hours ago Number of shares and voting rights - July 2026 (In French only)
